Denali grants Takeda options to neurology antibodies

Denali Therapeutics Inc. (NASDAQ:DNLI) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) options to co-develop and co-commercialize neurodegenerative disorder candidates ATV:BACE1/Tau, ATV:TREM2 and an undisclosed discovery-stage program.

The biotech is to receive $40 million

Read the full 310 word article

User Sign In